Omnitus syrup 0.8mg / ml 200ml fl

$7.04

Omnitus syrup 0.8mg / ml 200ml fl

Quantity:

SKU: 881029491 Categories: , , Tags: ,

Description

Composition
Active substance:
1 ml of syrup contains:
Butamirata citrate 0.8 mg.
Excipients:
Sorbitol 70% (nekristalliziruyuschy) – 405,00 mg Glycerol – 290.00 mg Saccharin Sodium – 0.60 mg Benzoic acid – 1.15 mg, vanillin – 0.60 mg, anise oil – 0.15 mg ethanol 96% – 3.00 l of sodium hydroxide – 0.10 mg purified water – up to 1.00 ml.
Description:
Prozrachnaya, bestsvetnaya or yellowish shade, c vyazkaya liquid odor of vanilla.
Product form:
Syrup 0.8 mg / ml. 200 ml of the product in the dark glass vial III hydrolytic group, a sealed polyethylene cap with tamper-evident. The top side of the lid opening scheme applied vial. 1 vial together with measuring spoon of polypropylene (volume of 5 ml, at the risk of volume 2.5 ml) and the instruction for medical use the drug in a pile of cardboard.
Contraindications
Increased sensitivity to the drug, pregnancy (I term), lactation, children under 3 years. Fructose intolerance (preparation comprises sorbitol).
Dosage
0.8 mg / ml
Indications
Dry cough from any cause (for colds, flu, whooping cough and other conditions). cough suppression in the preoperative and postoperative period, during surgery, bronchoscopy.
Interaction with other drugs
Any drug interactions are not described for butamirata. In the period of treatment is not recommended to drink alcohol, and drugs that suppress the central nervous system (hypnotics, neuroleptics, tranquilizers, etc..). Due to the fact that butamirata suppresses the cough reflex, avoid simultaneous use of expectorants to avoid accumulation of mucus in the airways of the risk of bronchospasm and respiratory tract infections.
Overdose
Symptoms: dizziness, drowsiness, nausea, vomiting, diarrhea, incoordination, decreased blood pressure.
Treatment: gastric lavage; activated charcoal, saline laxatives, symptomatic therapy (if indicated).
pharmachologic effect
Pharmacological group:
Antitussive central action.
Pharmacological properties:
Antitussive, expectorant provides moderate bronchodilatory and anti-inflammatory effect.
Butamirata citrate is neither chemical nor farmakologicheski alkaloidami akin to opium and has a direct effect on the cough center, improves spirometry and blood oxygenation.
Pharmacodynamics:
Butamirata, Omnitus® active substance preparation is a centrally acting antitussive. It does not apply to alkaloidam opium either chemically or farmakologicheski. It does not produce dependence or addiction. Suppresses cough, having a direct effect on the cough center. It has bronchodilatory effect (expands bronchi). It helps to alleviate respiratory spirometry improves (reduces airway resistance) and blood oxygenation (saturates the blood with oxygen).
Pharmacokinetics:
Absorption – high. After oral syrup in a dose containing 150 mg butamirata citrate maximum plasma concentration of the main metabolite (2-phenylbutyric acid) was observed after 1.5 hours and is 6.4 ug / ml, when receiving tablets with modified release (50 mg), respectively, – 9 h and 1.4 ug / ml. The half syrup – 6 hours, for tablets – 13 hours no cumulative effect.. Butamirata tsitrat rapidly hydrolyzed in plazme 2-fenilmaslyanuyu acid and dietilaminoetoksietanol. Oba these metabolita, obladayuschie takzhe antitussive effect, largely bound to plasma proteins, which explains their long presence in the plasma. Subsequently major metabolite 2-fenilmaslyanaya kislota 14C is oxidized to p-hydroxy-2-phenylbutyric acid. All three metabolita pochkami output, wherein the acidic metabolity svyazany mainly with glucuronic acid.
Pregnancy and breast-feeding
There are no data on the safety of drugs in pregnancy, and it passes through the placental barrier. Use of the drug in the I trimester of pregnancy is contraindicated. In II and III trimester of pregnancy, the use of the drug may be the case if the expected benefit to the mother outweighs the potential risk to the fetus. It is not known whether the active substance penetrates the drug or its metabolites in breast milk, therefore the use of the drug in the breastfeeding period is not recommended.
Conditions of supply of pharmacies
Without recipe.
side effects
Classification of the incidence of adverse reactions: very common (> 1/10), common (
From the digestive system: rarely – nausea, diarrhea.
Allergic reactions: seldom – skin rash, itching, hives.
special instructions
As sweetener syrup comprises sorbitol and saccharin, and the drug can be used by patients with diabetes.
Omnitus® can cause dizziness and drowsiness, so the period of treatment must be careful when driving and performing other potentially hazardous activities that require high concentration and psychomotor speed reactions.
Storage conditions
At temperatures above 25 ° C in a consumer package. The vial was stored after opening in a consumer package at temperature from 15 to 25 ° C and use before the expiration date. Keep out of the reach of children.
Dosing and Administration
Inside, the food.
Syrup contains complete one measuring spoon (5ml)
Children:
3 to 6 years of age (15-22 kg) – 2 scoops (10 ml) of 3 raza daily between 6 and 9 years of age (22-30 kg) – 3 scoops (15 ml) at day 3 raza older than 9 years ( 40kg) – 3 scoops (15 ml) at day 4 raza
Adults: – 6 scoops (30 ml) at day 3 raza
If cough persists for more than 5 days after the start of treatment, you should consult a doctor. Instructions for opening the lid of the vial The vial is closed with a safety device to prevent the opening of its children. To open the bottle, you need to strongly press down on the lid and turn it counterclockwise. After application of the vial should be closed tightly, for that vial cap is necessary to again tighten firmly.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

STADA

There are no reviews yet.

Add your review